A cell type of mysterious origin
The center of antibody production lies in lymphoid germinal centers (GCs), the seat of the T follicular helper (Tfh) cell interaction with B cells. Here, Tfh cells, a distinct subset of specialized CD4 + T cells, help B cells to undergo proliferation, isotype switching, and somatic hypermutation to form high-affinity antibodies (1, 2) . Our understanding of lymphoid Tfh cells is derived largely from studies in mice. Surgical human lymph node biopsies for research are not practical; however, recent studies suggest that fine-needle aspiration of lymph nodes (3) could prove to be a promising alternative. The discovery of lymphocytes with Tfh-like properties in human peripheral blood (4) naturally sparked a new era of investigation by researchers hoping that this circulating population may be a more accessible record of events in secondary lymphoid organs (SLOs; refs. 5, 6). But conclusive proof of a lymphoid origin for circulating Tfh (cTfh) cells has been lacking.
Tfh cell development and traffic in lymph nodes
Lymphocyte traffic to and from SLOs has intrigued and fascinated immunologists for decades. Sir James Gowans demonstrated in 1964 that rat lymphocytes circulate from blood to lymphoid organs one to two times a day (7) . Lymphocytes are transported into lymph nodes via afferent lymphatic vessels in lymph that percolates through the subcapsular, medullary, and cortical sinuses. They exit via efferent lymphatic vessels that merge into the thoracic duct, which empties into the subclavian vein (8) . Another portal for entry of lymphocytes into SLO is via high endothelial venules, which are specialized blood vessels in the paracortex (8), suggesting a plausible vascular route of lymphoid cell egress from SLO. Cues that regulate lymphocyte entry, retention, and exit from SLO are not fully understood and are regulated by a number of receptor/ligand interactions and gradients (9, 10) . Key examples are CCR7/CCL21 for lymphocyte homing into lymph nodes, CXCR5/CCL13 for follicular trafficking of CXCR5 + Tfh cells, and sphingosine-1-phosphate receptor 1 (SIPR1)/SIP for lymphocyte egress into efferent lymphatics that contain high concentrations of SIP. Cell-intrinsic circadian clocks and adrenergic nerve activity also influence lymphocyte retention in SLO (11) .
Inside the lymph node, CD4 + T cells that are activated by DCs in the T cell zone acquire distinct Tfh-associated characteristics (CXCR5 + CCR7 lo PD-1 + ICOS + , high BCL-6), as they embark on a purposeful journey with the sole commitment of helping B cells, each step being dependent upon cognate interaction with B cells. Migrating to the border of the B cell follicle, Tfh cells uniquely cross into the follicle and ultimately engage in the GC reaction as effector Tfh cells. Thereafter, the Tfh might die, revert to memory cells that remain in the same follicle, or traffic out as memory Tfh cells to adjacent follicles. A fourth possibility, investigated by Vella et al. in this issue (12) , is that GC Tfh cells exit out of the lymph node via the thoracic duct into the circulation.
Proving the origin of cTfh cells
The first step by Vella et al was to establish distinct phenotypic identities of lymphoid Tfh cells as total Tfh cells (CXCR5 + PD-1 + ), and GC Tfh cells (CXCR5 bright PD-1 bright , herein referred to as Br/Br), which were gated from a nonnaive lymphoid CD4 + T cell population inclusive of memory and effector CD4 + T cells. A unique component of this study was the analysis of lymph obtained by cannulation of the thoracic duct of human volunteers. They found that frequency of total and Br/Br Tfh cells was higher in SLO than thoracic duct lymphocytes (TDL) and lowest in blood ( Figure 1 ). The study cautions that tonsils differ from other SLO in frequencies of Tfh cells and shows feasibility of the nonhuman primate model in this type of research.
Abundant data were generated by Vella et al. (12) to support the relationship of Br/Br Tfh cells in TDL with GC Tfh cells in SLO. Notably, the overall phenotypic profile of TDL Tfh cells was similar to that of lymph node Tfh cells, with the exception of chemokine receptors CXCR3, CCR6, and CCR4 and the mucosal-trafficking integrin a 4 b 7 , which were all higher in thoracic duct Tfh cells, as expected for cells required to Tfh cell egress from SLO to populate and sustain the cTfh cells. Establishing the link of the cTfh cells to GC Tfh cells, however, was more challenging. First, the extreme paucity and even absence of Br/Br cTfh cells in the blood was unexpected and was attributed mainly to a shortened residency time calculated as one-tenth that of circulating CD4 + T cells. Second, cTfh cells resembled TDL dim/dim Tfh cells rather than Br/Br Tfh cells in their transcriptomic and epigenetic profiles and TCR clonotype, implying that a majority of cTfh cells were recirculating resting cells. It was the observation that the TCR sequences of TDL Br/Br Tfh cells overlapped with the TCR of cTfh cells far more than with other TDL Tfh subsets that provided the clue supporting entry of Br/Br Tfh cells from TDL into the pool of cTfh cells. To strengthen evidence for presence of GC cTfh cells in blood, Vella et al. (12) types, with changes in locus accessibility that correlated with transcription, and evidence of tonsillar GC Tfh cell signature in both. Importantly, chromatin regions of genes associated with Tfh cell function, such as IL-21 or CXCL13, were more accessible in lymph node GC Tfh cells and TDL Br/Br Tfh cells than in any of the other Tfh subsets evaluated. Further transcriptomic and epigenetic studies of known egress pathways and chemokine pathways in defined Tfh cell subsets could yield additional clues into how balance between genes involved in instructing GC Tfh cell trafficking is regulated; accessible open chromatin regions on particular genes could steer the balance between signals that regulate retention versus egress.
A dramatic reduction of circulating CXCR5 + CD4 + T cells was observed in patients given the S1PR inhibitor fingolimod (FTY720), supporting the concept of migrate to various tissues. Compared with GC Tfh cells, S1PR1 was highly expressed in TDL Br/Br Tfh cells, while CD69, a marker of tissue residency and a negative regulator of S1PR1, was downregulated (13), implying egress from SLO into the thoracic duct. Future studies may benefit by taking into consideration the impact of circadian cycles that also influence lymphocyte retention, such as by β2 adrenergic receptor-mediated signals (11) .
Transcriptional and epigenetic profiling of Tfh cells in different compartments further established the similarity between TDL Br/Br Tfh cells and lymph node GC Tfh cells. Both cell types displayed a common core transcriptional program, with an enrichment of tissue egress-associated genes, such as those encoding S1PR1, S1PR4, and Kruppel-like factor 2 in TDL Tfh cells. Epigenetic analyses also identified commonalities between the two cell that is present in both the GC and thoracic duct and has similar transcriptional and phenotypic characteristics in both locations; however, this population was present at a lower frequency in the thoracic duct than in the lymph nodes. cTfh cells with a similar phenotypic profile were also detectable in blood, but in even lower frequencies. An activated subset (ICOS + CD38 + ) of cTfh cells that are believed to be vaccine responsive, contained cells with similarities to thoracic duct and lymphoid GC Tfh cells. These studies provide evidence that a population of circulatory Tfh cells originated in the GC of lymph nodes, thereby connecting the biology of Tfh cells in blood to Tfh cells in lymphoid tissue.
The importance of PD-1 in GC Tfh cels is unquestionable for SLO, but its role in cTfh cells is unclear and basal CD38 expression decreases with age (22) . Are there minimal essential criteria for classifying Tfh cells in circulation? CXCR5 expression in memory CD4 + T cells with IL-21 production capability may suffice as overall cTfh cell markers. For GC cTfh cells, ICOS expression appears critical even in a quiescent state. Stimulus-induced CD40L or equivalent markers demonstrate antigen specificity (23, 24) . Now may be an opportune time to perform quantitative and qualitative investigations in vaccination/infection protocols in the context of age and clinical states to arrive at a unifying consensus. At the same time, assessing B cell helper function is critical. A plasmablast response (such as occurs on day seven after immunization) is unparalleled as an indicator of GC activity (25) . The identification of a true GCderived cTfh cell subset is a highly desirable goal for its utility as a biomarker to monitor lymphoid GC Tfh cell activity and as a therapeutic target. The study by Vella et al. has paved the way for future research of cTfh cells in health and disease.
turned to an alternate GC-like cTfh phenotype in blood, the ICOS + CD38 + subset, which was more abundant than the Br/Br phenotype. Previously, this group had demonstrated recurrent oligoclonal expansions of the ICOS + CD38 + cTfh cell subset 7 days after successive yearly influenza vaccinations in volunteers (14, 15) . Here, they show transcriptional and epigenetic similarity of ICOS + CD38 + cTfh cells to thoracic duct Br/Br Tfh cells and SLO GC Tfh cells as well as higher S1PR1 expression than ICOS -CD38 -cTfh cells. With these observations, the study comes close to establishing ties of ICOS + CD38 + cTfh cells with SLO GC Tfh cells; however, a direct comparison of CD38 + ICOS + Tfh cells in each of the three compartments would have clinched this relationship.
Concluding remarks
This study is important in that it has provided the best link so far between Tfh cells in lymph nodes, thoracic duct, and peripheral blood; a key contribution is the direct examination in humans of Tfh cells in thoracic duct compared with those in lymph nodes and blood. A burning question has been whether the cTfh cell pool contains an identifiable GC-experienced subset. The field is somewhat complex, and several studies have delineated cTfh and GC-like cTfh cell subsets with markers that overlap, but are not identical (Table 1 and refs. 4, 14, 16-21) . Heterogeneity of cTfh subsets, transient marker expression, or dependence on antigen pose challenges in this context.
Table 1. Conceptualized markers for GC Tfh cells in lymph nodes, GC-derived Tfh cells in the thoracic duct, circulating GC-like Tfh cells, and circulating non-GC Tfh cells

Marker
Lymph node Thoracic duct Circulation Circulation Marker combinations for GC cTfh cells commonly used include PD-1 + ICOS + CD38 + (12, 14) , PD-1 + ICOS + (17) , and PD-1 hi CCR7 lo (18) after gating on nonnaive CD4 + T cells, total CXCR5 + CD4 + T cells, and memory CXCR5 + CD4 + T cells, respectively. C Markers used to identify GC-like cTfh cells by Vella et al. in this issue (12) and previously (14) by the same group.
GC Tfh cells A Br/Br Tfh cells GC cTfh cells B non-GC cTfh cells
